We expect Q2 EBITDA of SEK117m, 2% below consensus of SEK120m (results due at 07:30 CET on 23 August). Focus will likely be on the pace of recovery following bird flu and campylobacter findings as well as the recently acquired Manor Farms and progress in Finland. We reiterate our BUY recommendation and SEK64 target price.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.